The S&amp;P 500 has had a rough 2026. Johnson &amp; Johnson has not. JNJ (NYSE:JNJ) is up 11% year-to-date, just beat first-quarter revenue estimates by half a billion dollars, and crossed $100 billion in annual revenue for the first time in its history. While the broader market hunts for footing, one of Wall Street’s oldest blue-chip names is quietly putting up its best numbers in years.



What’s driving it — and whether it can last — is a more complicated story. One that involves a 64-year dividend streak, a blockbuster cancer drug pipeline, thousands of pending lawsuits, and a nearly unanimous buy call from Wall Street analysts who’ve seen all of it and still like the stock.



Johnson &amp; Johnson (NYSE:JNJ) has always occupied a singular place in both corporate America and on Wall Street.



Exhibit A: JNJ is the only company in the world that can freely use the Red Cross symbol, thanks to a special act of Congress. “No other company in the world owns such a license,” says Gardner Harris, author of No More Tears: The Dark Secret of Johnson &amp; Johnson. “The Red Cross symbol is the most cherished in healthcare, one that engenders feelings of trust, respect, and admiration. J&amp;J’s ability to link its own brand with a universally recognized emblem of care and reassurance is priceless.”



That’s just for starters. Among institutional investors, Johnson &amp; Johnson has long been a “buy and hold” cornerstone, and for straightforward reasons. The stock checks nearly every box serious money managers look for in a core holding: durable earnings growth, recession resistance, steady and growing dividends, and revenue streams diversified enough that no single setback can knock the whole thing over.



For years, some analysts have called JNJ a “sleep well at night” stock. Is that still the right call in 2026? Here’s what the latest data and the analysts who cover it most closely say.



A Routinely Robust Recommendation



Let’s start with the consensus view.



Trading at $230 per share and up 11% year-to-date, a Benzinga review of analyst sentiment from Leerink Partners, Barclays, and Stifel shows approximately 12% share-price upside from current levels, with an average price target of $257.



Benzinga’s analysis flags JNJ as a top pick primarily because of its strong performance in MedTech and Vision, as well as plans to spin off its Ortho business in 2027 and the upcoming launch of TECNIS PureSee. “JNJ’s focus on double-digit sales growth and disciplined capital allocation makes it a favorable investment choice,” the analysis noted, “with expansion opportunities in the Asia Pacific region.”



Recent analyst activity reinforces that view. On May 13, Leerink Partners analyst David Risinger upgraded JNJ to Outperform from Market Perform with a $265 price target. In March, Barclays’ Matt Miksic reiterated a Hold with a $255 target. Last month, Stifel’s Rick Wise raised his price target from $220 to $250, citing an “all-around-positive ‘beat and raise’ performance” from management. RBC maintained its Outperform rating after what it called a “strong first-quarter performance,” while Bernstein highlighted 5.3% organic sales growth despite significant patent headwinds.



TD Cowen, which kept its Buy rating with a $250 target, said JNJ “boasts the key qualities we seek in pharma stocks.”



Live on Sunday: The Short-Term Strategy for Trading Oil, VIX, and SPY Volatility



Oil has been making violent moves on every new Iran update, while volatility and positioning continue setting up fast intraday swings underneath the surface. Chris Capre is breaking down the exact SPY levels, VIX behavior, and momentum setups he's watching right now across semis, energy, and short-term directional trades. He'll also show how options flows and gamma positioning can help traders stay ahead of sudden reversals instead of reacting after they happen. Some of the sharpest moves in this market are developing within hours. Save Your Seat Here



Diversification Is the Whole Game



One reason analysts stay bullish regardless of near-term noise: J&amp;J is not really a single company. It’s 28 of them, each generating more than $1 billion a year.



Unlike pure-play pharmaceutical companies that rise and fall with a handful of blockbuster drugs, J&amp;J operates across both Innovative Medicine and MedTech, two businesses large enough that weakness in one can be absorbed by strength in the other. That structural diversification is what keeps institutional investors comfortable holding the stock through rough patches.



The numbers support it. In Q1 2026, J&amp;J reported $24.1 billion in sales, up 9.9% and ahead of Wall Street’s $23.6 billion estimate. Innovative Medicine grew 11%, MedTech grew 7.7%, and the pharmaceutical division alone generated $15.4 billion, up 11.2% from $13.9 billion a year earlier. For full-year 2026, J&amp;J now expects approximately $100.8 billion in revenue, the first time in company history it has crossed the $100 billion threshold, and adjusted EPS of approximately $11.55 at the midpoint.



A Dividend King, by a Wide Margin



J&amp;J doesn’t just pay dividends, it has raised them every year for 64 consecutive years, earning Dividend King status with room to spare. (The threshold for that designation is 50 consecutive years of increases.)



The most recent hike, announced in April and payable in May, was a 3.1% increase from $1.30 to $1.34 per share per quarter. That brings the annual dividend to $5.36 per share, up from $5.20. Since 2021, J&amp;J has raised its dividend five times, at an average annual increase of 5.37%.



That combination of consistency and growth makes JNJ a natural magnet for retirees, pension funds, and income-focused institutional managers, investors who prize durable cash flow and disciplined management above almost everything else. J&amp;J reliably delivers both.



Oncology: A Burgeoning Revenue Engine



Beyond the headline numbers, there’s a specific reason analysts are increasingly excited about J&amp;J’s long-term trajectory: oncology.



J&amp;J generated more than $25 billion in oncology sales in 2025, led by two blockbusters. Darzalex, used to treat multiple myeloma, continues to drive strong global demand. Carvykti, J&amp;J’s CAR-T cell therapy, is viewed by several analysts as one of the company’s most important future growth drivers. Meanwhile, newer immunology products like Tremfya are helping offset revenue lost to biosimilar competition for Stelara.



CEO Joaquin Duato has made no secret of the strategy: concentrate investment in high-growth therapeutic areas, oncology, neuroscience, immunology, and build a clear path to double-digit growth by 2030. Analysts appear increasingly convinced it’s working.



MedTech is part of that story, too. With sales up 7.7% to $8.6 billion year-over-year, the division spans cardiovascular devices, orthopedics, surgical systems, and robotic-assisted surgery. Analysts have specifically flagged J&amp;J’s Ottava robotic surgery platform as a potential powerhouse in what is expected to be one of healthcare’s fastest-growing markets.



A Few Notes of Caution



JNJ is not a risk-free investment, and no honest analyst is claiming otherwise.



The company still faces thousands of pending talcum-powder lawsuits, creating a legal liability overhang that is difficult to fully quantify. Stelara, one of J&amp;J’s highest-earning drugs, saw sales drop roughly 60% year-over-year in the latest quarter following biosimilar competition. Patent expirations remain a structural headwind, and J&amp;J faces a competitive M&amp;A environment as it pursues early-stage pharmaceutical deals.



Some analysts also believe management’s guidance is deliberately conservative, possibly limiting near-term upside. Leerink’s Risinger, despite his recent upgrade, described the updated outlook as “conservative” relative to the company’s actual operating performance.



Benzinga’s analysis flagged the litigation risks specifically, noting they “could weigh on the company’s financial performance in the coming years, despite its strong position in the MedTech market and a diverse portfolio of products.”



Most analysts, however, appear comfortable with those risks — because of what’s on the other side of the ledger: scale, diversification, a blue-chip dividend track record, and a pipeline pointing toward double-digit growth. In a market where the S&amp;P 500 has spent 2026 looking for its footing, JNJ offers something increasingly rare: a large-cap stock that income investors and growth investors can both defend owning.



For investors who need to sleep at night, that might be exactly enough.

Johnson & Johnson (JNJ) stock has risen 11% year-to-date, outperforming the struggling S&P 500. The company reported record revenue, surpassing $100 billion for the first time, and maintains a 64-year dividend streak. Analysts remain bullish, with a consensus price target of $257, citing strong performance in MedTech and a diversified business model that mitigates risks. Recent upgrades from analysts reflect confidence in JNJ's growth potential and strategic plans, including a spin-off of its Ortho business in 2027.

- Johnson & Johnson (NYSE:JNJ) has performed well in 2026, reporting an 11% year-to-date increase and exceeding revenue estimates, while the S&P 500 struggles.  
- Analysts maintain a bullish outlook, attributing favorable conditions to JNJ's diverse revenue streams and consistent dividend increases, despite ongoing legal challenges and market competition.  
- The company’s focus on oncology and MedTech, coupled with a strong historical performance, positions JNJ as a stable investment choice for both income and growth-focused investors.

One Blue-Chip Stock Is Up 11% While the S&P 500 Struggles